Prospects for personalized immunosuppression: Pharmacologic tools - A review

Transplantation Proceedings

Volumn 36, Issue 3, 2004, Pages 687-689

  Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

BLOOD LEVEL; CONFERENCE PAPER; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; GENE EXPRESSION; GENE MUTATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MICROEMULSION; PHARMACOGENETICS; PRIORITY JOURNAL; REDUCTION; RISK FACTOR; TREATMENT OUTCOME;

DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 2042443114     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.03.011     Document Type: Conference Paper

References (15)

1. Johnston A., Holt D.W. Immunosuppressant drugs - the role of therapeutic drug monitoring. Br J Clin Pharmacol. 52:(Suppl 1):2001;61S
2. Dunn C.J., Wagstaff A.J., Perry C.M., et al. Cyclosporin an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs. 61:2001;1957
3. Wong S.H. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 313:2001;241
4. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients are the statins mechanistically similar? Pharmacol Ther. 80:1998;1
5. Wallemacq P.E., Verbeeck R.K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 40:2001;283
6. Deierhoi M.H., Haug M. Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin Transplant. 14:2000;439
7. Levy G., Thervet E., Lake J., et al. Patient management by Neoral C(2) monitoring an international consensus statement. Transplantation. 73:2002;S12
8. Mourad M., Wallemacq P., Konig J., et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients is it necessary? Clin Pharmacokinet. 41:2002;319
9. Nicholls A.J. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/ pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem. 31:1998;329
10. Kahan B.D., Napoli K.L., Kelly P.A., et al. Therapeutic drug monitoring of sirolimus correlations with efficacy and toxicity. Clin Transplant. 14:2000;97
11. van Hooff J.P., Boots J.M., van Duijnhoven E.M., et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc. 31:1999;54S
12. Halloran P.F., Helms L.M., Kung L., et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 68:1999;1356
13. Koefoed-Nielsen P.B., Gesualdo M.B., Poulsenb J.H., et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant. 2:2002;173
14. Albrecht W., Storck M., Pfetsch E., et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit. 22:2000;283
15. Danesi R., Mosca M., Boggi U., et al. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today. 6:2000;475